Orris

adenl.ate cyclase mechanism in enzymatic receptor in short

Reading File
Finding Sources
Searching Images

adenylate cyclase G protein cAMP second messenger signaling pathway diagram

Reading File
Reading File
Loading Image

Adenylate Cyclase Mechanism in Enzymatic (G-Protein Coupled) Receptors

Adenylate cyclase (AC) is the key effector enzyme in the cAMP second messenger pathway, operating downstream of G-protein coupled receptors (GPCRs). Here is the step-by-step mechanism:

Step-by-Step Mechanism

1. Ligand Binding A hormone or neurotransmitter (e.g., glucagon, adrenaline, norepinephrine via β-receptors) binds to its specific GPCR on the cell surface.
2. G-Protein Activation (Gs)
  • At rest, the stimulatory G-protein (Gs) exists as a trimeric complex (α, β, γ subunits) with GDP bound to the α-subunit.
  • Ligand-bound receptor interacts with the Gs complex → the α-subunit releases GDP and binds GTP.
  • The Gα-GTP subunit dissociates from the βγ complex.
3. Adenylate Cyclase Activation
  • The free Gα-GTP subunit binds to and activates membrane-bound adenylate cyclase.
  • AC catalyzes the conversion: ATP → cAMP (3',5'-cyclic AMP) + pyrophosphate.
4. Signal Amplification via PKA
  • cAMP binds to the regulatory (R) subunits of Protein Kinase A (PKA), which is normally inactive as a tetramer (2R + 2C subunits).
  • Binding of cAMP to R subunits causes a conformational change → catalytic (C) subunits are released and become active.
  • Active PKA phosphorylates target proteins on serine/threonine residues, activating some enzymes and inhibiting others.
5. Signal Termination
  • The intrinsic GTPase activity of the α-subunit hydrolyzes GTP → GDP, switching off AC.
  • cAMP is degraded to 5'-AMP by phosphodiesterase (PDE), terminating the signal.

Inhibitory Pathway (Gi)

Some receptors (e.g., α2-adrenergic, opioid) couple to Gi proteins, which inhibit adenylate cyclase, reducing cAMP production - the opposite effect.

Downstream Effects of PKA Activation

PKA phosphorylates many targets:
  • Metabolic enzymes (e.g., activates glycogen phosphorylase, inhibits glycogen synthase)
  • Ion channels (rapid effects on excitability)
  • CREB (cAMP Response Element Binding protein) - enters the nucleus and regulates gene transcription via CRE elements (longer-lasting effects)

Diagram

cAMP signaling pathway: Gs activates adenylate cyclase → cAMP → PKA → CREB → transcription
FIGURE: Basic organization of the cAMP signaling pathway - Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Summary Table

StepComponentEvent
1GPCRLigand binds receptor
2Gs protein (α-subunit)GDP → GTP; α-subunit dissociates
3Adenylate cyclaseATP → cAMP
4PKAR subunits release C subunits → protein phosphorylation
5PDEcAMP → 5'-AMP (signal off)
Key examples of hormones using this pathway: Glucagon, Epinephrine (β-receptors), ACTH, TSH, PTH, FSH, LH, ADH (V2 receptor).
Sources: Basic Medical Biochemistry - A Clinical Approach 6e, p. ~1793; Kaplan & Sadock's Comprehensive Textbook of Psychiatry, p. 564-565

adenylate cyclase function in heart

Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Loading Image
Loading Image

Adenylate Cyclase Function in the Heart

Adenylate cyclase (AC) sits at the center of cardiac adrenergic signaling. Its activation controls heart rate, contractility, and relaxation through cAMP/PKA-mediated phosphorylation of calcium-handling proteins.

Trigger: β1-Adrenergic Stimulation

Catecholamines (norepinephrine from sympathetic nerves; epinephrine from the adrenal medulla) bind β1-adrenergic receptors (predominant in the heart) on the sarcolemma.
  • β1-receptor → Gs protein (αs subunit) → activates adenylate cyclase
  • AC converts ATP → cAMP
  • cAMP activates Protein Kinase A (PKA)

PKA Phosphorylates 4 Key Cardiac Targets

TargetLocationEffect
L-type Ca²⁺ channels (LTCC)SarcolemmaIncreased Ca²⁺ influx → stronger contraction
Ryanodine receptor (RyR2)SR membraneEnhanced Ca²⁺ release from SR
Phospholamban (PLN)SR membraneRelieves SERCA2A inhibition → faster Ca²⁺ reuptake → faster relaxation + increased SR Ca²⁺ load
Troponin I (TnI)MyofilamentReduces Ca²⁺ sensitivity → aids relaxation

Net Cardiac Effects

  1. Positive Chronotropy (increased heart rate) - cAMP speeds pacemaker If current in SA node; phosphorylation of SR proteins accelerates spontaneous Ca²⁺ cycling in pacemaker cells
  2. Positive Inotropy (increased contractility) - more Ca²⁺ enters and is released, greater force of contraction
  3. Positive Lusitropy (faster relaxation) - phospholamban phosphorylation activates SERCA2A, pulling Ca²⁺ back into the SR faster; TnI phosphorylation reduces myofilament Ca²⁺ sensitivity
  4. Positive Dromotropy (faster conduction) - enhanced AV node conduction
  5. Metabolic boost - PKA also stimulates glycolysis, lipolysis, and the citrate cycle to meet increased energy demand

Inhibitory Counterpart (Gi)

  • Parasympathetic (ACh via M2 receptors on cardiac pacemaker and myocytes) → Gi → inhibits AC → ↓ cAMP → bradycardia and reduced contractility
  • α2-adrenergic receptors also couple to Gi and inhibit AC

Diagram 1 - Cardiomyocyte β-adrenergic → Adenylate Cyclase → Ca²⁺ handling

β-adrenergic receptor → Gs → adenylate cyclase → cAMP → PKA → LTCC, RyR2, SERCA/PLN phosphorylation in cardiomyocyte
Cardiomyocyte signaling - Goldman-Cecil Medicine

Diagram 2 - Full β-adrenergic → cAMP → PKA pathway showing inotropic and lusitropic effects

β-adrenergic agonist → αs-GTP → adenylate cyclase → cAMP → PKA → increased rate of contraction, peak force, and relaxation
Inotropic and lusitropic effects of β-adrenergic stimulation - Harrison's Principles of Internal Medicine 22E

Clinical Relevance

Drug/ConditionMechanismEffect on AC
β-blockers (metoprolol, carvedilol)Block β1-receptorReduce AC activation → lower HR and contractility
PDE3 inhibitors (milrinone)Prevent cAMP degradationProlong AC's product → increase contractility (used in acute heart failure)
Dobutamineβ1-agonistDirectly stimulates AC activation → positive inotropy
Heart failureDownregulation of β1-receptors and ACBlunted cAMP response → reduced reserve
Sources: Goldman-Cecil Medicine, p. 412-413; Harrison's Principles of Internal Medicine 22E, p. 1892-1893; Medical Physiology (Boron), Table 23-1

can adenylate cyclase cause tachycardia

Finding Sources
Finding Sources
Reading File
Reading File

Yes - Adenylate Cyclase Directly Causes Tachycardia

Here is the full explanation of how and why:

The Mechanism: AC → cAMP → Faster SA Node Firing

Step-by-step in pacemaker cells (SA node):
  1. Catecholamines (norepinephrine / epinephrine) bind β1-adrenergic receptors on SA node pacemaker cells
  2. Gs protein → activates adenylate cyclase → ↑ cAMP
  3. cAMP acts on two key ion channels in the SA node:
ChannelEffect of ↑cAMPResult
HCN channels (If - "funny current")cAMP directly binds HCN and increases If (Na⁺/K⁺ inward current)Speeds up phase 4 diastolic depolarization
L-type & T-type Ca²⁺ channelsPKA phosphorylation → ↑ ICaFurther accelerates depolarization slope; shifts threshold to more negative voltage
  1. Net result: Phase 4 (diastolic depolarization) becomes steeper → SA node fires more frequently → tachycardia

Two Clocks Accelerated by cAMP

The SA node uses two interdependent pacemaking mechanisms, both driven by cAMP:
  • Membrane clock (Voltage clock): cAMP directly binds the HCN channel (If), increasing the diastolic inward current that depolarizes the cell toward threshold
  • Calcium clock: cAMP/PKA phosphorylates RyR2 and phospholamban → enhanced spontaneous SR Ca²⁺ cycling → triggers more Na⁺/Ca²⁺ exchanger (NCX) inward current → further depolarization
Both clocks are "wound up" by adenylate cyclase activation.

Opposite: How AC Inhibition Causes Bradycardia

Parasympathetic stimulation (ACh via M2 receptors) activates Gi protein → inhibits adenylate cyclase → ↓ cAMP → If decreases, ICa decreases → slower phase 4 depolarization → bradycardia. M2 also directly opens GIRK K⁺ channels, hyperpolarizing the cell further.

Summary Table: AC Activity and Heart Rate

AC ActivityTriggercAMP LevelHeart Rate
Activated (Gs)Sympathetic, β1-agonists, adrenaline, stress↑↑Tachycardia
Inhibited (Gi)Parasympathetic (ACh), β-blockers, adenosine↓↓Bradycardia

Clinical Conditions Linked to AC-Driven Tachycardia

Condition / DrugHow AC is Over-Activated
PheochromocytomaExcess catecholamines → constant β1 stimulation → AC overdrive
ThyrotoxicosisThyroid hormone upregulates β-receptors and AC sensitivity
Dobutamine / Salbutamol (β-agonists)Directly activate β1/β2 → AC → ↑ cAMP → tachycardia (side effect)
PDE inhibitors (milrinone)Prevent cAMP breakdown → same effect as prolonged AC activation
Anesthesia awareness / pain / anxietySympathetic surge → NE/Epi release → AC activation

Drug That Blocks the cAMP Effect on If (Without Blocking AC)

Ivabradine specifically blocks HCN channels (the direct target of cAMP in the SA node) - it slows heart rate without blocking AC or affecting contractility. This confirms that the cAMP → If pathway is the key tachycardia mechanism.
Sources: Medical Physiology (Boron & Boulpaep), p. 792; Fuster and Hurst's The Heart 15th Ed., p. SA node automaticity section
This is a shared conversation. Sign in to Orris to start your own chat.